Literature DB >> 10652219

Real-time monitoring of the hybridization reaction: application to the quantification of oligonucleotides in biological samples.

V Boutet1, V Delaunay, M C De Oliveira, D Boquet, J M Grognet, J Grassi, J R Deverre.   

Abstract

We describe here a competitive hybridization assay using TRACE technology which can be used for real-time monitoring of oligonucleotide hybridization. This assay quantifies all kinds of oligonucleotides in biological fluids without extraction. The assay makes use of two different probes and involves a fluorescent transfer process. As fluorescence measurements are not destructive, they can be sequentially repeated, thereby allowing comparison of the hybridization kinetics and binding strength of chemically modified backbone oligonucleotides (>0.5 nM) in biological media. The assay was validated for pharmacokinetic analysis of phosphodiester and phosphorothioate oligonucleotides in plasma and in different organs (liver, kidneys, lungs, spleen) at low concentrations (0.4 mg/kg, corresponding to clinical doses). Respective sensitivities for phosphodiester and phosphorothioate were 0.2 and 0.8 pmol/ml in plasma and 2 and 8 pmol/g in tissues, which allow to recover intact phosphorothioate sequences in some organs even after 24 h. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652219     DOI: 10.1006/bbrc.2000.2088

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  A homogeneous europium cryptate-based assay for the diagnosis of mutations by time-resolved fluorescence resonance energy transfer.

Authors:  E Lopez-Crapez; H Bazin; E Andre; J Noletti; J Grenier; G Mathis
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

2.  Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake.

Authors:  Jianjun Zhang; Mohammad Zafrullah; Xia Yang; Xianglei Yin; Zhigang Zhang; Zvi Fuks; Richard Kolesnick
Journal:  Cancer Biol Ther       Date:  2008-09-15       Impact factor: 4.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.